COVID-19

News

Verily taps Oncimmune tech for 'long COVID' study

Alphabet's Verily Life Science has contracted UK biotech Oncimmune to investigate autoantibodies in people who have developed long-lasting symptoms after COVID-19 infection, a condition kno

News

Synairgen slumps as inhaled COVID drug fails pivotal test

UK biotech Synairgen saw the value of its shares crater after its inhaled interferon beta therapy SNG001 was found to provide no benefit to people hospitalised with COVID-19.

R&D

Examining COVID’s impact on clinical research participant di...

The clinical research industry has long struggled with participant diversity.

News

COVID jabs now offered to all children aged 5 to 11 across U...

England and Northern Ireland have followed Wales and Scotland in offering healthy children aged between five and 11 a low-dose COVID-19 vaccine, making vaccination an option for a younger a

R&D

Why was R&D productivity up in 2021?

A recent report has found that R&D productivity rose vertiginously during 2021, but how much of this was organic and how much can be attributed to the pandemic?

News

Lilly bags US okay for rival to GSK's COVID-19 drug Xevudy

Eli Lilly has been granted an emergency use authorisation from the FDA for bebtelovimab, its second COVID-19 antibody drug and a rival to GlaxoSmithKline and Vir Biotech's fast-growing Xevu

Verily taps Oncimmune tech for 'long COVID' study

Synairgen slumps as inhaled COVID drug fails pivotal test

Examining COVID’s impact on clinical research participant di...

COVID jabs now offered to all children aged 5 to 11 across U...

Why was R&D productivity up in 2021?

Lilly bags US okay for rival to GSK's COVID-19 drug Xevudy

Despite study bust, Vistagen still hopes to file anxiety dru...

Discover a new era of healthcare panel engagement: Grounded ...

COVID-19

Editor's Picks